stonks4u
Sign up free
ADIL logo

ADIL Adial Pharmaceuticals, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$3.98
-0.41 (-9.34%)

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the…

Market Cap: $3.82Mwww.adial.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$3.96 – $4.37
52-Week Range
$1.31 – $10.75
Volume
$48.6K
Market Cap
$3.82M
50-Day Avg
$3.01
200-Day Avg
$3.91
Prev Close
$4.39
Open
$4.11

Valuation & Ratios

P/E Ratio
-0.46
EPS
$-11.93
P/B Ratio
0.70
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
4.42
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-151.2%
Return on Assets
-117.3%
FCF Yield
-176.6%
EV/EBITDA
0.28

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-7.98M$-11.93
2024$0.00$-13.20M$-17.75
2023$0.00$-7.00M$-136.00
2022$0.00$-12.73M$-299.50
2021$0.00$-19.42M$-653.00

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

7of 8 quarters beat consensus

Typical surprise +21.1% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$-11.25 vs $-1.03miss
  • Wed, May 13$-1.48 vs $-2.73beat
  • Tue, Mar 10$-1.81 vs $-2.10beat
  • Thu, Nov 13$-2.00 vs $-2.25beat
  • Wed, Aug 13$-0.18 vs $-0.22beat
  • Wed, May 14$-0.34 vs $-0.50beat

Estimates and results for ADIL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by ADIL officers and directors.

Bought
$709k

14 trades

Sold
$40.0bn

2 trades

  • Coastlands Capital Lpbought
    10 percent owner·1,233 @ $2.75·$3k·Jul 16, 2026·filing
  • Coastlands Capital Lpbought
    10 percent owner·2,000 @ $2.65·$5k·Jul 14, 2026·filing
  • Coastlands Capital Lpbought
    10 percent owner·1,700 @ $2.70·$5k·Jul 10, 2026·filing
  • Coastlands Capital Lpbought
    10 percent owner·10,053 @ $2.79·$28k·Jul 9, 2026·filing
  • Coastlands Capital Lpbought
    10 percent owner·25,000 @ $2.60·$65k·Jun 29, 2026·filing
  • Young Wendy B.bought
    director·36,378 @ $0.00·$36·Jun 12, 2026·filing
  • Schuyler Kevinbought
    director·700 @ $2.74·$2k·Sep 29, 2023·filing
  • Newman James W. Jr.bought
    director·5,000 @ $2.72·$14k·Dec 30, 2021·filing

84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

ADILhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·5h ago·Neutral

    Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline

    View source ↗